NCT07215559

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Reduction With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and With Type 2 Diabetes

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.

Conditions

• Obesity
• Overweight
• Diabetes Mellitus, Type 2

Interventions

Type	Name	Description
DRUG	Macupatide	Administered SC
DRUG	Eloralintide	Administered SC
DRUG	Macupatide Placebo	Administered SC
DRUG	Eloralintide Placebo	Administered SC

Timeline

• Start date: 2025-10-16
• Primary completion: 2027-03-01
• Completion: 2027-05-01
• First posted: 2025-10-10
• Last updated: 2026-03-02

Locations

38 sites across 4 countries: United States, Argentina, Australia, Puerto Rico

Regulatory

• FDA-regulated drug study